3190 results for «710»
3190 results
TEER in complex tricuspid regurgitation - LIVE case
14 Feb 2026 – From PCR Tokyo Valves 2026
A 79-year-old male with permanent AF, prior colorectal and prostate cancer, and a Mosaic bioprosthetic mitral valve implanted in 2016, presented with torrential tricuspid regurgitation and preserved LV function.
Three G5 clips were implanted: two anteroseptal (1 XTW and 1 XT) and one posteroseptal XTW.
LIVE Educational Case...
Hot topics and evidence on structural interventions in 2025 and 2026
14 Feb 2026 – From PCR Tokyo Valves 2026
Delve into the emerging clinical evidence and key hot topics shaping transcatheter interventions for aortic, mitral, and tricuspid valve diseases anticipated to influence clinical practice in 2025 and 2026. This session reviews stroke prevention, valve interventions across the three valves, and integrates recent and upcoming data...
Prevention and management of TAVI complications
14 Feb 2026 – From PCR Tokyo Valves 2026
This session addresses the prevention and management of major complications associated with transcatheter aortic valve implantation (TAVI). Attendees will gain a detailed understanding of mechanisms behind cerebral infarction, haemolysis, valve infolding, pacemaker implantation, and valve migration, along with expert strategies for recognition, decision-making, and bailout techniques...
Primary mitral TEER in small anatomy - LIVE case
15 Feb 2026 – From PCR Tokyo Valves 2026
An 89-year-old male with diabetes mellitus, hypertension, chronic kidney disease (eGFR: 46), and CAD with a history of NSTEMI and CTO of the RCA, presented with symptomatic primary mitral regurgitation (P1–P2 prolapse) and preserved LV function (56%).
One Pascal ACE device was implanted.
LIVE Educational Case from Nagoya...
Guidelines update
15 Feb 2026 – From PCR Tokyo Valves 2026
This session reviews the latest updates in the ESC/EACTS guidelines for structural heart disease, emphasizing their clinical implications and future trends. Participants will gain understanding of changes in aortic, mitral, and tricuspid valve recommendations, including new age cutoffs, asymptomatic disease management, and the evolving role of...
Future devices and techniques for structural heart disease
15 Feb 2026 – From PCR Tokyo Valves 2026
This session surveys the future landscape of structural heart disease treatment, addressing current limitations in transcatheter valve technologies and presenting emerging devices and techniques for aortic, mitral, and tricuspid valves. Attendees will gain insights into innovations poised to transform therapeutic options for structural heart disease.
TAILORED-CHIP: Tailored antiplatelet therapy for complex high-risk PCI
29 Aug 2025
Nicola Ryan provides her take on the results of TAILORED-CHIP presented by Duk-Woo Park at the ESC Congress 2025 in Madrid.
Author
TRI.fr trial - Multicentric randomised evaluation of the transcatheter edge-to-edge repair in the treatment of severe isolated secondary tricuspid regurgitation
31 Aug 2024
Alex Sticchi provides his take on the results of the TRI.FR trial presented by Erwan Donal at the ESC Congress 2024 in London.
Author
Top Interventional Trials presented at ACC.21
07 Jun 2021
Ali Nazmi Calik provides a summary and key take-aways and infographics of 9 major trials of interest to interventional cardiologists presented at ACC.21
Author
Impella percutaneous ventricular assist device malrotation in social media: a call to action
20 Apr 2023
The data from this study suggest that, from a SoMe perspective, correct Impella orientation is often overlooked, and that Impella malrotation is a common issue in real-world clinical practice, potentially associated with relevant complications.
Author
Author
Author
Author
Author
